TabletsClinical Overview
Cabergoline Tablets IP 0.5 mg is a potent, long-acting synthetic ergoline dopamine D2-receptor agonist on the WHO Model List of Essential Medicines. By directly stimulating D2 receptors on anterior pituitary lactotroph cells, it potently suppresses prolactin secretion with a biological half-life of 63 to 69 hours. Indicated for the treatment of hyperprolactinemia (due to idiopathic causes, prolactin-secreting pituitary adenomas/prolactinomas, or empty sella syndrome), inhibition/suppression of physiological postpartum lactation, and prevention of ovarian hyperstimulation syndrome (OHSS) in ART cycles.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with food and water to minimize nausea and postural hypotension: For hyperprolactinemia: Initial dose is 0.25 mg to 0.5 mg once or twice weekly (e.g. Monday and Thursday); titrate monthly by 0.5 mg weekly increments based on serum prolactin levels (typical maintenance dose: 0.5 to 1 mg twice weekly). For lactation suppression: 1 mg as a single oral dose within 24 hours postpartum. Take with evening meal or bedtime.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, dizziness, orthostatic hypotension, headache, fatigue, drowsiness, constipation, abdominal pain, and depression. Rare/Severe: Cardiac valvulopathy, pulmonary/pleural/retroperitoneal fibrosis (associated with cumulative high doses), psychotic episodes, impulse control disorders (pathological gambling, hypersexuality), and angina.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in uncontrolled hypertension, history of cardiac valvular disorders, history of pulmonary, pericardial, or retroperitoneal fibrotic disorders, and toxemia of pregnancy. Perform baseline echocardiogram prior to long-term therapy and every 6-12 months thereafter. Monitor blood pressure closely.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.